ScholarLens Back to search
2013•Pediatric RheumatologyOpen access

PReS-FINAL-2041: Macrophage activation syndrome in the children with systemic juvenile idiopathic arthritis during the course of tocilizumab

Ekaterina I. Alexeeva, Rina V. Denisova, Saniya I Valieva, Tatyana M. Bzarova, K. Isayeva, Tatyana V. Sleptsova, EA Mitenko, Е. G. Chistyakova, Anna N. Fetisova

Open full text 0 citations

Abstract

Systemic juvenile idiopathic arthritis (sjia) is a chronic inflammatory disease characterized by prolonged systemic and synovial inflammation. Life-threatening complication of sjia is the macrophage activation syndrome (MAS). Tocilizumab (TCZ) is highly effective in children with sjia. However, MAS remains under the treatment of TCZ.

Open-access reader

About this research paper

What this paper is about

Systemic juvenile idiopathic arthritis (sjia) is a chronic inflammatory disease characterized by prolonged systemic and synovial inflammation. Life-threatening complication of sjia is the macrophage activation syndrome (MAS). Tocilizumab (TCZ) is highly effective in children with sjia. However, MAS remains under the treatment of TCZ.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Systemic juvenile idiopathic arthritis (sjia) is a chronic inflammatory disease characterized by prolonged systemic and synovial inflammation. Life-threatening complication of sjia is the macrophage activation syndrome (MAS). Tocilizumab (TCZ) is highly effective in children with sjia. However, MAS remains under the treatment of TCZ.

Key concepts: Tocilizumab, Macrophage activation syndrome, Medicine, Rheumatology, Juvenile, Arthritis, Internal medicine, Interleukin 6

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
PReS-FINAL-2041: Macrophage activation syndrome in the children with systemic juvenile idiopathic arthritis during the course of tocilizumab — Research Paper | ScholarLens